已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract 3501: A novel CD2-targeted costimulatory bispecific antibody platform for enhancing CD3 T cell engager-based cancer immunotherapy

癌症免疫疗法 免疫疗法 双特异性抗体 癌症研究 T细胞 癌症 抗体 医学 单克隆抗体 免疫系统 免疫学 内科学
作者
Gerhard Niederfellner,Welbeck Danquah,Mélanie Pichery,Thomas Watts Eden,Aurélien Boyance,Lise Pasquet,Valérie Desroys du Roure,Alice Marchand,Marion Mars,Ellen Gumz,Mylène Gador,L Valente,Marion Contini,Lukas Czernecki,S. Shanmuganathan,Markus Dangl
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 3501-3501
标识
DOI:10.1158/1538-7445.am2025-3501
摘要

Abstract CD3-based T cell engagers (TCEs) are a clinically successful class of bispecific antibodies that has delivered 11 approved agents to date, albeit primarily for treatment of blood cancers. These agents provide a strong signal 1 for redirecting polyclonal T cells, regardless of their native specificity, to kill cancer cells. However, when only receiving signal 1 for prolonged periods of time without a costimulatory signal, T cells become anergic and exhausted. In part due to the lack of costimulatory signals in the tumor microenvironment, TCEs have had limited therapeutic success in solid tumor indications so far. Interestingly, single cell RNA sequencing data from multiple solid tumor types revealed that a high percentage of tumor infiltrating T cells express high levels of CD2 but not CD28 or other costimulatory receptors. Based on a proprietary antibody that binds a unique epitope on the costimulatory T cell receptor CD2, we have developed a novel bispecific antibody platform (BiTco) that provides costimulation to T cells via CD2 in the context of a tumor-associated antigen. Using primary human T cells as effectors in vitro, we found that CD2 and CD28 costimulation potentiated T cell activation and T cell-mediated tumor cell killing to a comparable extent. However, the CD2 BiTco format triggered less pronounced cytokine release making it a potentially safer clinical option. Moreover, we demonstrated that, unlike CD28, our CD2 BiTco format also provides robust costimulation to CD28-negative CD8 T cells that possess high cytotoxic capacity and constitute the majority of CD8 T cells found in elder patients. Further, by using a fixed sub-efficacious dose of CD3 TCE we simulated in vitro a clinical setting where reduced expression of tumor antigen can result in loss of CD3 TCE monotherapy efficacy. When adding increasing doses of CD2 BiTco in this setting we could fully restore optimal anti-tumor cytotoxicity and T cell activation. In addition, we knocked out CD58 on tumor target cells to mimic loss of expression of this primary ligand of CD2, which is another known mechanism of immune escape by tumors. We showed that BiTco treatment allows to recover and even enhance TCE-mediated T cell cytotoxicity in the absence of tumor-expressed CD58. Finally, we established a BT474 clone 5 xenograft model using immunodeficient mice, in which a human T cell compartment was reconstituted by injection of human PBMCs. In this in vivo model we showed that combination treatment of CD2 BiTco with a sub-efficacious dose of a CD3 TCE resulted in highly effective control of tumor growth by human T cells. In summary, combination therapy with our differentiated CD2 BiTco platform can improve CD3 TCE response and limit acquired resistance mediated by loss of tumor antigen and/or CD58. Citation Format: Gerhard J. Niederfellner, Welbeck Danquah, Melanie Pichery, Thomas Eden, Aurelien Boyance, Lise Pasquet, Virginie Roure, Alice Marchand, Marion Mars, Ellen Gumz, Mylene Gador, Lou Valente, Marion Contini, Lukas Czernecki, Sanjit Shanmuganathan, Markus Dangl. A novel CD2-targeted costimulatory bispecific antibody platform for enhancing CD3 T cell engager-based cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3501.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汪欣怡完成签到 ,获得积分10
刚刚
1秒前
CodeCraft的应助被爱you采纳,获得10
2秒前
科研通AI6.4的应助被hulai采纳,获得10
2秒前
CHean发布了新的文献求助20
3秒前
hanshishengye完成签到 ,获得积分0
5秒前
5秒前
8秒前
成就舞仙完成签到,获得积分10
10秒前
10秒前
大力的无声完成签到,获得积分10
11秒前
平常映雁发布了新的文献求助10
11秒前
lb完成签到,获得积分10
13秒前
14秒前
小二郎的应助被Clearday采纳,获得10
14秒前
二呆熊发布了新的文献求助10
15秒前
小丑完成签到,获得积分10
15秒前
LUYAO1完成签到 ,获得积分10
15秒前
xl_c完成签到 ,获得积分10
15秒前
15秒前
K2C完成签到,获得积分10
20秒前
ZM完成签到,获得积分10
20秒前
Ava的应助被二呆熊采纳,获得10
22秒前
小巧的白容完成签到,获得积分10
22秒前
23秒前
无花果的应助被Flynn采纳,获得10
23秒前
科研通AI2S的应助被科研通管家采纳,获得50
23秒前
lukou关注了科研通微信公众号
24秒前
Nole的应助被科研通管家采纳,获得10
24秒前
ding的应助被科研通管家采纳,获得10
24秒前
英俊的铭的应助被科研通管家采纳,获得10
24秒前
mountainbike完成签到,获得积分10
24秒前
24秒前
Nole的应助被科研通管家采纳,获得10
24秒前
打打的应助被科研通管家采纳,获得10
24秒前
CAOHOU的应助被科研通管家采纳,获得10
24秒前
传奇3的应助被科研通管家采纳,获得10
25秒前
疯狂的凡梦完成签到 ,获得积分10
25秒前
dmmmm0903发布了新的文献求助30
26秒前
ttang11完成签到,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179547
求助须知:如何正确求助?哪些是违规求助? 9569910
关于积分的说明 21807373
捐赠科研通 7775016
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2556999
邀请新用户注册赠送积分活动 2478760